PLX
Protalix Biotherapeutics Inc
NYSE MKT: PLX · HEALTHCARE · BIOTECHNOLOGY
$2.02
+3.06% today
Updated 2026-05-06
Market cap
$170.81M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-0.08
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
WallStSmart proprietary scores
18
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F5.0
Quality
C+2.0
Profitability
F4.7
Valuation
C—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$11.00
+444.55%
12-Month target
—
—
Intrinsic (DCF)
$2.81
Margin of safety
-3.91%
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $795000.00 — positive
Risks
- Thin margins at -12.50%
- Revenue declining -49.90% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $47.64M | $65.49M | $53.40M | $52.74M | $52.74M |
| Net income | $-14.93M | $8.31M | $2.93M | $-6.60M | $-5.50M |
| EPS | — | — | — | — | $-0.08 |
| Free cash flow | $-25.63M | $-2.47M | $7.39M | $-13.63M | $795000.00 |
| Profit margin | -31.33% | 12.69% | 5.49% | -12.52% | -12.50% |
Peer comparison
Smart narrative
Protalix Biotherapeutics Inc trades at $2.02. Our Smart Value Score of 18/100 indicates the stock is weak. TTM revenue stands at $52.74M. with profit margins at -12.50%. Our DCF model estimates intrinsic value at $2.81.
Frequently asked questions
What is Protalix Biotherapeutics Inc's stock price?
Protalix Biotherapeutics Inc (PLX) trades at $2.02.
Is Protalix Biotherapeutics Inc overvalued?
Smart Value Score 18/100 (Grade F, Strong Sell). DCF value $2.81.
What is the price target of Protalix Biotherapeutics Inc (PLX)?
The analyst target price is $11.00, representing +444.6% upside from the current price of $2.02.
What is the intrinsic value of Protalix Biotherapeutics Inc (PLX)?
Based on our DCF model, intrinsic value is $2.81, a -3.9% margin of safety versus $2.02.
What is Protalix Biotherapeutics Inc's revenue?
TTM revenue is $52.74M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE MKT
CurrencyUSD
Quick metrics
P/S ratio3.24x
ROE-14.40%
Beta-0.09
50D MA$2.45
200D MA$2.10
Shares out0.08B
Float0.07B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—